AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35687403 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based interpersonal psychotherapy (IPT) modules with guided support
Number of subjects: 15
Study 35687751 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-mediated upper limb rehabilitation
Number of subjects: 36
Study 35687751 — intervention group
Group type: COMPARATOR
Intervention: Stretching and range-of-motion exercises
Number of subjects: 36
Study 35687781 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple guideline-based medical therapy (GBMT)
Number of subjects: 2680
Study 35687781 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual guideline-based medical therapy (GBMT)
Number of subjects: 2680
Study 35687781 — intervention group
Group type: EXPERIMENTAL
Intervention: Single guideline-based medical therapy (GBMT)
Number of subjects: 2680
Study 35687781 — intervention group
Group type: COMPARATOR
Intervention: No guideline-based medical therapy (GBMT)
Number of subjects: 2680
Study 35687896 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular/Ocular Motor Screening for Concussion (VOMS)
Number of subjects: 79
Study 35687896 — intervention group
Group type: COMPARATOR
Intervention: Buffalo Concussion Bike Test (BCBT)
Number of subjects: 79
Study 35687896 — intervention group
Group type: COMPARATOR
Intervention: National Institutes of Health Toolbox-Cognition Battery (NIHTB-CB)
Number of subjects: 79
Study 35688166 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI exposure >0 to 6 months
Number of subjects: 29340
Study 35688166 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI exposure >6 to 12 months
Number of subjects: 29340
Study 35688166 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI exposure >12 to 24 months
Number of subjects: 29340
Study 35688166 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI exposure >24 to 36 months
Number of subjects: 29340
Study 35688166 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI exposure >36 months
Number of subjects: 29340
Study 35688166 — intervention group
Group type: COMPARATOR
Intervention: No INSTI exposure
Number of subjects: 29340
Study 35688366 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35688465 — intervention group
Group type: EXPERIMENTAL
Intervention: SM03, an anti-CD22 recombinant IgG1 mAb
Number of subjects: 0
Study 35688465 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35688469 — intervention group
Group type: EXPERIMENTAL
Intervention: DPC score (0-15 points) based on dialysis duration, pretransplant intact parathyroid hormone, and serum calcium level
Number of subjects: 2
Study 35688469 — intervention group
Group type: COMPARATOR
Intervention: Single-time measurement of DPC score
Number of subjects: 2
Study 35688554 — intervention group
Group type: EXPERIMENTAL
Intervention: DuoBody-CD40×4-1BB
Number of subjects: 0
Study 35688554 — intervention group
Group type: EXPERIMENTAL
Intervention: DuoBody-CD40×4-1BB with PD-1 blocking antibodies
Number of subjects: 0
Study 35688625 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study across five cohorts
Number of subjects: 0
Study 35688679 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg plus erlotinib (dose levels: 50, 100, 150 mg daily)
Number of subjects: 37
Study 35688701 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital Nerve Stimulation (ONS)
Number of subjects: 7
Study 35688802 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4547 administered with anastrozole or letrozole
Number of subjects: 52
Study 35689142 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-case bariatric surgery
Number of subjects: 30
Study 35689142 — intervention group
Group type: COMPARATOR
Intervention: Inpatient surgery
Number of subjects: 30
Study 35689206 — intervention group
Group type: EXPERIMENTAL
Intervention: Xerostomia (measured by Xerostomia Inventory)
Number of subjects: 87
Study 35689290 — intervention group
Group type: EXPERIMENTAL
Intervention: Literacy-adapted, electronic family history tool
Number of subjects: 0
Study 35689453 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Healing Index (EHI)
Number of subjects: 131
Study 35689453 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Healing Index (EHI) <20 at 6 months
Number of subjects: 131
Study 35689453 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Healing Index (EHI) <20 (combined all time points)
Number of subjects: 131
Study 35689453 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in EHI
Number of subjects: 131
Study 35689544 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvocidib administered in combination with cytarabine and mitoxantrone (ACM) for R/R AML
Number of subjects: 0
Study 35689544 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvocidib administered in combination with cytarabine/daunorubicin (A + 7 + 3) for newly diagnosed AML
Number of subjects: 0
Study 35689597 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper airway stimulation (UAS) treatment
Number of subjects: 24
Study 35689737 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily for 16 weeks in addition to existing topical therapy
Number of subjects: 152
Study 35689793 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 64
Study 35689793 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical (NS) controls
Number of subjects: 64
Study 35690072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg per day and intravenous atezolizumab 1200 mg once every 3 weeks
Number of subjects: 132
Study 35690303 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of obstetrical practice to offset risk for CM
Number of subjects: 0
Study 35690498 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib + bevacizumab
Number of subjects: 105
Study 35690537 — intervention group
Group type: EXPERIMENTAL
Intervention: CT lung imaging measurements and conventional demographic and clinical measurements
Number of subjects: 527
Study 35690537 — intervention group
Group type: EXPERIMENTAL
Intervention: CT measurements alone
Number of subjects: 527
Study 35690537 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and lung function measurements alone
Number of subjects: 527
Study 35690720 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR phenotype algorithm for identifying ADHD cases
Number of subjects: 51293
Study 35690720 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of ADHD-specific medications in the algorithm
Number of subjects: 51293
Study 35690720 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD codes and medication searches
Number of subjects: 51293
Study 35690720 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without psychiatric and neurological disorders)
Number of subjects: 51293
Study 35690762 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line ART
Number of subjects: 347
Study 35690762 — intervention group
Group type: EXPERIMENTAL
Intervention: Not switching ART regimen
Number of subjects: 347
Study 35690762 — intervention group
Group type: COMPARATOR
Intervention: Switching ART regimen
Number of subjects: 347
Study 35690798 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cannabis use
Number of subjects: 6348
Study 35690798 — intervention group
Group type: EXPERIMENTAL
Intervention: Former cannabis use
Number of subjects: 6348
Study 35690827 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 60
Study 35690827 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 60
Study 35690827 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 60
Study 35690827 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 60
Study 35690891 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 days of cannabis abstinence facilitated by contingency management, motivational interviewing, psychoeducation, and coping-skills training
Number of subjects: 11
Study 35690891 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 days of cannabis abstinence
Number of subjects: 11
Study 35690924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 73
Study 35691028 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic approaches recommended by the Spanish Society of Transplantation (SET), GESITRA-SEIMC, and REIPI for managing MDR GNB infections in SOT recipients.
Number of subjects: 0
Study 35691028 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinational INCREMENT-SOT consortium findings.
Number of subjects: 0
Study 35691028 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently approved antibiotics positioning in SOT setting.
Number of subjects: 0
Study 35691544 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-99677, a selective targeted covalent MK2 inhibitor
Number of subjects: 0
Study 35691614 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital interventions (e.g., electronic monitoring devices, short message services)
Number of subjects: 15207
Study 35691614 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital interventions
Number of subjects: 15207
Study 35692051 — intervention group
Group type: COMPARATOR
Intervention: Case-control study using questionnaires on candidate risk factors for GC
Number of subjects: 2400
Study 35692051 — intervention group
Group type: COMPARATOR
Intervention: Case-control tissue sampling study using proteome, genome, microbiome, and immune analyses
Number of subjects: 2400
Study 35692051 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational study testing knowledge dissemination on GC risk factors and symptoms
Number of subjects: 2400
Study 35692260 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg)
Number of subjects: 21832
Study 35692260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21832
Study 35692547 — intervention group
Group type: EXPERIMENTAL
Intervention: ADR-001
Number of subjects: 6
Study 35692935 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation (TENS)
Number of subjects: 66
Study 35692935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 35693790 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated Fatty Acids (SFAs) in case children
Number of subjects: 0
Study 35693790 — intervention group
Group type: COMPARATOR
Intervention: Polyunsaturated Fatty Acids (PUFAs) in control children
Number of subjects: 0
Study 35693874 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonavalent HPV vaccine
Number of subjects: 2275
Study 35693874 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine
Number of subjects: 2275
Study 35693874 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal vaccine
Number of subjects: 2275
Study 35694160 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 0
Study 35694160 — intervention group
Group type: COMPARATOR
Intervention: Flavanone-free control drink
Number of subjects: 0
Study 35694163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting combined with exercise (IF + EX)
Number of subjects: 36
Study 35694163 — intervention group
Group type: COMPARATOR
Intervention: Exercise group (EX)
Number of subjects: 36
Study 35694163 — intervention group
Group type: COMPARATOR
Intervention: Intermittent fasting group (IF)
Number of subjects: 36
Study 35694168 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery measured with the Pearlin Mastery Scale (PMS)
Number of subjects: 32588
Study 35694435 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait mindfulness (measured by the Five Facet Mindfulness Questionnaire and the Decentering subscale of the Experiences Questionnaire)
Number of subjects: 153
Study 35694435 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait mindfulness
Number of subjects: 153
Study 35694435 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions
Number of subjects: 153
Study 35694653 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care and Collaborative Model (SCCM)
Number of subjects: 584
Study 35694653 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 584
Study 35694680 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% chitosan bioactive hemostatic dressing
Number of subjects: 600
Study 35694680 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-ferrate based topical hemostasis disc
Number of subjects: 600
Study 35694680 — intervention group
Group type: COMPARATOR
Intervention: Standard pneumatic airbladder-based compression device
Number of subjects: 600
Study 35694826 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal CFR (Coronary Flow Reserve)
Number of subjects: 1102
Study 35694826 — intervention group
Group type: COMPARATOR
Intervention: Structural CMD (abnormal CFR with abnormal MR)
Number of subjects: 1102
Study 35694826 — intervention group
Group type: COMPARATOR
Intervention: Functional CMD (abnormal CFR with normal MR)
Number of subjects: 1102
Study 35694826 — intervention group
Group type: COMPARATOR
Intervention: Normal microvascular function
Number of subjects: 1102
Study 35694826 — intervention group
Group type: COMPARATOR
Intervention: Microvascular resistance parameters
Number of subjects: 1102
Study 35695002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and FOLFIRI in combination with daily oral G-NLC (ginsenoside-modified nanostructured lipid carrier containing curcumin)
Number of subjects: 44
Study 35695137 — intervention group
Group type: EXPERIMENTAL
Intervention: App for detecting atrial fibrillation
Number of subjects: 0
Study 35695332 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel Discontinuation Group
Number of subjects: 3456
Study 35695332 — intervention group
Group type: COMPARATOR
Intervention: Non-Clopidogrel Discontinuation Group
Number of subjects: 3456
Study 35695332 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 subgroup analysis
Number of subjects: 3456
Study 35695334 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic JAK inhibitors plus standard of care
Number of subjects: 11145
Study 35695536 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant NDV (rNDV)
Number of subjects: 0
Study 35695536 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control assays for rNDV
Number of subjects: 0
Study 35695563 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib in combination with endocrine therapy
Number of subjects: 0
Study 35695609 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of NUSAP1
Number of subjects: 0
Study 35695609 — intervention group
Group type: EXPERIMENTAL
Intervention: NUSAP1 expression
Number of subjects: 0
Study 35695609 — intervention group
Group type: EXPERIMENTAL
Intervention: NUSAP1
Number of subjects: 0
Study 35695616 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium (4 mg/day) for 180 days
Number of subjects: 12
Study 35695616 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 12
Study 35695646 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant combinations
Number of subjects: 198
Study 35695646 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline clinical characteristics (insomnia, reduced need for sleep, self-confidence, cheerfulness, comorbid panic disorder)
Number of subjects: 198
Study 35695646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of baseline SI and insomnia
Number of subjects: 198
Study 35695943 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuryn Monitoring System (Potrero Medical, Hayward, CA) for continuous urinary output (CUO) and intra-abdominal pressure (IAP) measurements
Number of subjects: 137
Study 35696069 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 113
Study 35696069 — intervention group
Group type: COMPARATOR
Intervention: Control (no rhPTH(1-84))
Number of subjects: 113
Study 35696133 — intervention group
Group type: EXPERIMENTAL
Intervention: 44-channel suprachoroidal retinal prosthesis with a stimulation charge density limited to 32 µC/cm2 per phase
Number of subjects: 4
Study 35696157 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/ml protonated nicotine at 15 W
Number of subjects: 45
Study 35696157 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/ml protonated nicotine at 30 W
Number of subjects: 45
Study 35696157 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/ml protonated nicotine at 15 W
Number of subjects: 45
Study 35696157 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/ml protonated nicotine at 30 W
Number of subjects: 45
Study 35696157 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/ml protonated nicotine at 15 W
Number of subjects: 45
Study 35696157 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/ml protonated nicotine at 30 W
Number of subjects: 45
Study 35696182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipodystrophy
Number of subjects: 18
Study 35696182 — intervention group
Group type: EXPERIMENTAL
Intervention: Receptoropathy
Number of subjects: 18
Study 35696182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovary+ patients
Number of subjects: 18
Study 35696182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovary- patients
Number of subjects: 18
Study 35696182 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 18
Study 35696702 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cetuximab followed by concurrent radiotherapy with cetuximab 250 mg/m2/cisplatin 40 mg/m2 (DL1)
Number of subjects: 21
Study 35696702 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with cetuximab 200 mg/m2 and cisplatin 30 mg/m2 (DL2)
Number of subjects: 21
Study 35696702 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with cetuximab 250 mg/m2 and cisplatin 30 mg/m2 (DL3)
Number of subjects: 21
Study 35696702 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 21
Study 35696702 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cetuximab
Number of subjects: 21
Study 35697255 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban underdose (10 mg/d)
Number of subjects: 2215
Study 35697255 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban standard-dose (15 mg/d)
Number of subjects: 2215
Study 35697266 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal sponge cytology
Number of subjects: 22
Study 35697332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vebicorvir (VBR) 300 mg + Entecavir (ETV) 0.5 mg
Number of subjects: 25
Study 35697332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + Entecavir (ETV) 0.5 mg
Number of subjects: 25
Study 35697530 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 9
Study 35697530 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization with embryo transfer (ET)
Number of subjects: 9
Study 35697530 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization with day 2 embryos
Number of subjects: 9
Study 35697530 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization with day 5 embryos
Number of subjects: 9
Study 35697530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy outcomes
Number of subjects: 9
Study 35697530 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery outcomes
Number of subjects: 9
Study 35697530 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term health measures
Number of subjects: 9
Study 35697530 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial outcomes
Number of subjects: 9
Study 35697532 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted reproductive technology (ART)
Number of subjects: 559
Study 35697532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation induction (OI)
Number of subjects: 559
Study 35697532 — intervention group
Group type: EXPERIMENTAL
Intervention: Twins conceived using ART or OI
Number of subjects: 559
Study 35697532 — intervention group
Group type: EXPERIMENTAL
Intervention: Twins conceived using OI
Number of subjects: 559
Study 35697532 — intervention group
Group type: COMPARATOR
Intervention: Children conceived using ART or OI
Number of subjects: 559
Study 35697729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil emulsion (FO) adjunct to 3+7 chemotherapy
Number of subjects: 30
Study 35697729 — intervention group
Group type: COMPARATOR
Intervention: Historical comparison to LAM2001 trial
Number of subjects: 30
Study 35697890 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation of premature ventricular contractions (PVC)
Number of subjects: 64
Study 35697890 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation of ventricular tachycardia (VT)
Number of subjects: 64
Study 35697890 — intervention group
Group type: COMPARATOR
Intervention: Intensified medical therapy
Number of subjects: 64
Study 35698155 — intervention group
Group type: EXPERIMENTAL
Intervention: DEXA+ (dexamethasone 6 mg/day intravenous for 10 days)
Number of subjects: 158
Study 35698155 — intervention group
Group type: COMPARATOR
Intervention: DEXA- (not treated with corticosteroids)
Number of subjects: 158
Study 35698155 — intervention group
Group type: EXPERIMENTAL
Intervention: DEXA+
Number of subjects: 158
Study 35698155 — intervention group
Group type: EXPERIMENTAL
Intervention: VAP (in general)
Number of subjects: 158
Study 35698201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis-associated critical illness
Number of subjects: 888
Study 35698201 — intervention group
Group type: COMPARATOR
Intervention: Non-sepsis-associated critical illness
Number of subjects: 888
Study 35698232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (pre-treatment)
Number of subjects: 0
Study 35698232 — intervention group
Group type: EXPERIMENTAL
Intervention: ER/SR calcium depletion
Number of subjects: 0
Study 35698232 — intervention group
Group type: EXPERIMENTAL
Intervention: MANF (mesencephalic astrocyte-derived neurotrophic factor)
Number of subjects: 0
Study 35698232 — intervention group
Group type: EXPERIMENTAL
Intervention: SEPN1 (Selenoprotein N)
Number of subjects: 0
Study 35698233 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Valve Replacement (DVR)
Number of subjects: 89
Study 35698233 — intervention group
Group type: COMPARATOR
Intervention: Aortic Valve Replacement with Mitral Valve Repair (AVR + MVP)
Number of subjects: 89
Study 35698233 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surgical techniques (DVR and AVR + MVP)
Number of subjects: 89